Comparative Efficacy and Safety of Dabigatran, Enoxaparin, and Rivaroxaban for Prophylaxis of Cancer-associated Venous Thromboembolism: A Single-center Randomized Trial

View at publisher Summarise with VIRAT
Authors: Pouya Yousefli, Farahnaz Ghahremanfard, Masoumeh Masoudian, Kobra Baharmpour, Mohsen Darabian, Bahador Bagheri
Cited by: 0
References: 32

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: The objective of this study was to compare the prophylactic efficacy of enoxaparin, dabigatran, and rivaroxaban in ambulatory patients with cancer. METHODS: In this randomized trial, patients were assigned to three groups: Group 1 received subcutaneous enoxaparin 40 mg daily (n = 35), Group 2 received oral dabigatran 150 mg daily (n = 11), and Group 3 received oral rivaroxaban 10 mg daily (n = 11) for a duration of three months. The primary outcomes were the incidence of Venous Thromboembolism (VTE) and bleeding events. RESULTS: The incidence of VTE was 2 (3.5%) in patients receiving enoxaparin and 1 (1.7%) in those receiving dabigatran (P > 0.05). No thromboembolic events were reported in patients administered rivaroxaban. One patient (1.7%) in the enoxaparin group experienced a major bleeding episode (P > 0.05), while no major bleeding events were observed in patients receiving dabigatran or rivaroxaban. DISCUSSION: Enoxaparin, dabigatran, and rivaroxaban are widely used for the prevention of VTE in patients with cancer. Although some previous studies have reported differences in bleeding and VTE risk, the present study did not demonstrate significant differences among enoxaparin, dabigatran, and rivaroxaban in VTE prevention. Notably, the risk of VTE is substantially influenced by the type of cancer, the modalities of anticancer treatment, and the patient's clinical status. CONCLUSION: The efficacy and safety of enoxaparin, dabigatran, and rivaroxaban for the prevention of VTE in patients with cancer appear to be comparable.

Fields of Study & Subjects

Venous Thromboembolism Diagnosis and Management Blood Coagulation and Thrombosis Mechanisms Atrial Fibrillation Management and Outcomes

Publication details

Journal / source
Cardiovascular & Hematological Agents in Medicinal Chemistry
Volume
24
Issue
1
Pages
71–78
Publication date
1 February 2026
Language
EN